We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




First X-Linked Mental Retardation Diagnostic Panel Developed

By LabMedica International staff writers
Posted on 27 Apr 2010
A range of genetic tests has been developed that are expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).

This panel marks the first time next-generation sequencing technology, combined with microarrays, Sanger sequencing, and traditional fragile-X testing, is being made clinically available to address this disorder, giving physicians a full range of reflex options to suit the needs of their patients.

The Ambry Genetics' (Aliso Viejo, CA, USA) XLMR SuperPANEL spans all levels of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of approximately 90 specific target genes. More...
Components include the XLMR Array Plus, the XLMR Next Gen Sequencing Panel, and individual sequencing tests including Fragile X. Testing can be customized for individual patients. The Sequencing Panel uses new and innovative technologies, including RainDance Technologies' (Lexington, MA, USA) RDT 1000 system for sequence enrichment with the Illumina genome analyzer IIx. Ambry has been an Illumina-certified service provider for research services since 2007.

"I'm very excited about the various technologies we applied to this suite of tests, and that we can develop similar tests for other complex disease states,” said Anja Kammesheidt, chief scientific officer at Ambry Genetics. "The new technologies create an important paradigm shift and allow us to comprehensively investigate complex genetic disorders in the same way monogenic disorders have been diagnosed for years.”

"Ambry Genetics is ideally suited to bring multigenic assays into the marketplace,” said Charles Dunlop, chief executive officer. "We've not only been performing services on these platforms for years with a very good understanding of the nuances of these technologies, but we also have over a decade of experience launching high information-content sequencing tests. We know how to deal with the interpretation issues that arise at the patient level, and our company is geared towards helping physicians with this type of information.”

Intellectual disability (also called mental retardation) is a lifelong impairment of cognitive and adaptive skills affecting approximately 2% - 3% of the general population. For approximately half of patients who have undergone extensive traditional evaluations, the cause remains unknown. About 10% - 15% of intellectual disability is attributed to genetic defects of the X chromosome and is called XLMR. The disorder affects as many as 1/1,000 to 1/600 males plus a significant number of females.

Ambry Genetics specializes in the application of new technologies to molecular diagnostics and genetics research.

Related Links:
Ambry Genetics


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.